Microbial Distribution and Antimicrobial Susceptibility Trends in Maxillofacial Infections from 2016 to 2025
Background: This study evaluated oral streptococcal distribution and antimicrobial susceptibility trends in maxillofacial infections to inform empirical antibiotic selection. Methods: Initial culture results from non-blood specimens were retrospectively reviewed for 437 infection episodes in 428 predominantly hospitalized patients during 2016–2025. Logistic regression using each patient’s first episode assessed annual trends in organism detection, non-susceptibility (intermediate or resistant results), and resistance. Multiple testing was addressed using the Benjamini–Hochberg procedure. Results: Hospitalization accounted for 428 of 437 episodes (97.9%). Oral streptococci were detected in 271 of 397 culture-positive episodes (68.3%), with annual proportions ranging from 52.6% to 83.8%. The Streptococcus anginosus group was detected in 158 episodes (39.8%). Ampicillin susceptibility was 76.5% for Streptococcus constellatus, 90.0% for Streptococcus anginosus, and 20.4% for the study-defined Streptococcus mitis/oralis group; corresponding ceftriaxone susceptibility was 95.5%, 96.3%, and 71.4%. No significant annual trends were found after correction for multiple testing in 15 analyses of organism detection, 21 organism–antibiotic analyses of non-susceptibility, or 14 analyses of resistance. Conclusions: Oral streptococci remained common, supporting their continued targeting in empirical therapy. High ceftriaxone susceptibility in Streptococcus constellatus and Streptococcus anginosus provides organism-specific microbiological information. Clinical efficacy and adequate coverage of coexisting organisms, including anaerobes, require separate evaluation.